vs

Side-by-side financial comparison of ARVINAS, INC. (ARVN) and STEM, INC. (STEM). Click either name above to swap in a different company.

STEM, INC. is the larger business by last-quarter revenue ($47.1M vs $41.9M, roughly 1.1× ARVINAS, INC.). STEM, INC. runs the higher net margin — -33.9% vs -83.8%, a 49.9% gap on every dollar of revenue. On growth, STEM, INC. posted the faster year-over-year revenue change (-15.6% vs -59.1%). Over the past eight quarters, STEM, INC.'s revenue compounded faster (36.1% CAGR vs 10.0%).

Arvinas, Inc. is a clinical-stage biotechnology company focused on developing targeted protein degradation therapies, including PROTAC molecules, to treat cancer and rare diseases. It operates primarily in the U.S. and global biopharma markets, advancing multiple pipeline candidates through clinical trials to address unmet medical needs.

StemCells, Inc. is a public biopharmaceutical company headquartered in Newark, California, that is developing purified human neural stem cells (HuCNS-SCs) in the hopes of treating central nervous system disorders and paralysis. StemCells' HuCNS-SCs have the ability to differentiate into the three main types of cells found in the central nervous system: neurons, astrocytes and oligodendrocytes.

ARVN vs STEM — Head-to-Head

Bigger by revenue
STEM
STEM
1.1× larger
STEM
$47.1M
$41.9M
ARVN
Growing faster (revenue YoY)
STEM
STEM
+43.5% gap
STEM
-15.6%
-59.1%
ARVN
Higher net margin
STEM
STEM
49.9% more per $
STEM
-33.9%
-83.8%
ARVN
Faster 2-yr revenue CAGR
STEM
STEM
Annualised
STEM
36.1%
10.0%
ARVN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ARVN
ARVN
STEM
STEM
Revenue
$41.9M
$47.1M
Net Profit
$-35.1M
$-16.0M
Gross Margin
48.9%
Operating Margin
-104.5%
-17.7%
Net Margin
-83.8%
-33.9%
Revenue YoY
-59.1%
-15.6%
Net Profit YoY
28.7%
68.8%
EPS (diluted)
$-0.48
$-4.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARVN
ARVN
STEM
STEM
Q4 25
$47.1M
Q3 25
$41.9M
$38.2M
Q2 25
$38.4M
Q1 25
$188.8M
$32.5M
Q4 24
$59.2M
$55.8M
Q3 24
$102.4M
$29.3M
Q2 24
$76.5M
$34.0M
Q1 24
$25.3M
$25.5M
Net Profit
ARVN
ARVN
STEM
STEM
Q4 25
$-16.0M
Q3 25
$-35.1M
$-23.8M
Q2 25
$202.5M
Q1 25
$82.9M
$-25.0M
Q4 24
$-45.1M
$-51.1M
Q3 24
$-49.2M
$-148.3M
Q2 24
$-35.2M
$-582.3M
Q1 24
$-69.4M
$-72.3M
Gross Margin
ARVN
ARVN
STEM
STEM
Q4 25
48.9%
Q3 25
35.5%
Q2 25
33.4%
Q1 25
32.4%
Q4 24
-4.4%
Q3 24
21.2%
Q2 24
27.6%
Q1 24
-95.0%
Operating Margin
ARVN
ARVN
STEM
STEM
Q4 25
-17.7%
Q3 25
-104.5%
-33.6%
Q2 25
-34.8%
Q1 25
37.8%
-65.0%
Q4 24
-98.1%
-84.4%
Q3 24
-58.9%
-493.2%
Q2 24
-63.4%
-1705.5%
Q1 24
-329.2%
-267.0%
Net Margin
ARVN
ARVN
STEM
STEM
Q4 25
-33.9%
Q3 25
-83.8%
-62.2%
Q2 25
527.8%
Q1 25
43.9%
-76.9%
Q4 24
-76.2%
-91.6%
Q3 24
-48.0%
-506.3%
Q2 24
-46.0%
-1712.6%
Q1 24
-274.3%
-283.9%
EPS (diluted)
ARVN
ARVN
STEM
STEM
Q4 25
$-4.40
Q3 25
$-0.48
$-2.84
Q2 25
$-1.79
Q1 25
$1.14
$-0.15
Q4 24
$-0.63
$-15.29
Q3 24
$-0.68
$-18.24
Q2 24
$-0.49
$-71.81
Q1 24
$-0.97
$-0.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARVN
ARVN
STEM
STEM
Cash + ST InvestmentsLiquidity on hand
$787.6M
$48.9M
Total DebtLower is stronger
$600.0K
Stockholders' EquityBook value
$564.4M
$-249.4M
Total Assets
$844.3M
$308.9M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARVN
ARVN
STEM
STEM
Q4 25
$48.9M
Q3 25
$787.6M
$43.1M
Q2 25
$40.8M
Q1 25
$954.3M
$58.6M
Q4 24
$1.0B
$56.3M
Q3 24
$1.1B
$75.4M
Q2 24
$1.2B
$89.6M
Q1 24
$1.2B
$112.8M
Total Debt
ARVN
ARVN
STEM
STEM
Q4 25
Q3 25
$600.0K
Q2 25
Q1 25
$700.0K
Q4 24
$800.0K
Q3 24
$800.0K
Q2 24
$900.0K
Q1 24
$900.0K
Stockholders' Equity
ARVN
ARVN
STEM
STEM
Q4 25
$-249.4M
Q3 25
$564.4M
$-235.7M
Q2 25
$-214.1M
Q1 25
$660.1M
$-417.5M
Q4 24
$561.7M
$-398.4M
Q3 24
$586.0M
$-344.1M
Q2 24
$600.2M
$-203.2M
Q1 24
$609.7M
$371.6M
Total Assets
ARVN
ARVN
STEM
STEM
Q4 25
$308.9M
Q3 25
$844.3M
$362.6M
Q2 25
$379.2M
Q1 25
$1.0B
$405.1M
Q4 24
$1.1B
$437.4M
Q3 24
$1.2B
$537.8M
Q2 24
$1.3B
$691.5M
Q1 24
$1.2B
$1.3B
Debt / Equity
ARVN
ARVN
STEM
STEM
Q4 25
Q3 25
0.00×
Q2 25
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARVN
ARVN
STEM
STEM
Operating Cash FlowLast quarter
$-59.1M
$8.2M
Free Cash FlowOCF − Capex
$-59.2M
FCF MarginFCF / Revenue
-141.3%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-361.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARVN
ARVN
STEM
STEM
Q4 25
$8.2M
Q3 25
$-59.1M
$11.4M
Q2 25
$-21.3M
Q1 25
$-88.9M
$8.5M
Q4 24
$-84.1M
$-14.7M
Q3 24
$-128.0M
$-9.4M
Q2 24
$50.3M
$-11.9M
Q1 24
$-97.5M
$-621.0K
Free Cash Flow
ARVN
ARVN
STEM
STEM
Q4 25
Q3 25
$-59.2M
Q2 25
Q1 25
$-89.3M
Q4 24
$-84.4M
Q3 24
$-128.7M
Q2 24
$49.6M
Q1 24
$-97.6M
FCF Margin
ARVN
ARVN
STEM
STEM
Q4 25
Q3 25
-141.3%
Q2 25
Q1 25
-47.3%
Q4 24
-142.6%
Q3 24
-125.7%
Q2 24
64.8%
Q1 24
-385.8%
Capex Intensity
ARVN
ARVN
STEM
STEM
Q4 25
Q3 25
0.2%
Q2 25
Q1 25
0.2%
Q4 24
0.5%
Q3 24
0.7%
Q2 24
0.9%
Q1 24
0.4%
Cash Conversion
ARVN
ARVN
STEM
STEM
Q4 25
Q3 25
Q2 25
-0.11×
Q1 25
-1.07×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons